Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer

Journal of Breast Cancer

Volumn 18, Issue 1, 2015, Pages 16-21

  Kim, Taeryung ^a   Han, Wonshik ^b   Kim, Min Kyoon ^b   Lee, Jun Woo ^b   Kim, Jisun ^b   Ahn, Soo Kyung ^b   Lee, Han Byoel ^b   Moon, Hyeong Gon ^b   Lee, Kyung Hun ^c   Kim, Tae Yong ^c   Han, Sae Won ^c   Im, Seock Ah ^c   Park, In Ae ^b   Kim, Ju Yeon ^d   Noh, Dong Young ^b  

^a Gachon University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Gyeongsang National University   (South Korea)

Author keywords

Biological markers; Neoadjuvant therapy; Triple negative breast neoplasms; Tumor suppressor protein p53

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TRIPLE NEGATIVE BREAST CANCER;

EID: 84925946400     PISSN: 17386756     EISSN: 20929900     Source Type: Journal    
DOI: 10.4048/jbc.2015.18.1.16     Document Type: Article

References (24)

1. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203.
2. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
3. Bozzetti C, Musolino A, Camisa R, Bisagni G, Flora M, Bassano C, et al. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am J Clin Oncol 2006;29:171-7.
4. Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, MouretReynier MA, et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008;13:1235-45.
5. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
6. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007;7:36.
7. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann Oncol 2003;14:428-32.
8. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6.
9. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009;26:344-9.
10. Jung SY, Han W, Lee JW, Ko E, Kim E, Yu JH, et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009;16:1112-21.
11. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008;10:R30.
12. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-8.
13. Mieog JS, van der Hage JA, van de Vijuer MJ, van de Velde CJ; Cooperating Investigators of the EORTC. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Eur J Cancer 2006;42:1369-79.
14. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111:27-44.
15. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011;13:R22.
16. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
17. Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, Ji ZY, et al. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One 2012;7:e39655.
18. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 2013;132:1227-31.
19. Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, et al. Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. Exp Ther Med 2011;2:257-64.
20. Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008;75:132-9.
21. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995;55:2487-9.
22. Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995;1:189-98.
23. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996; 74:78-85.
24. Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D’Amico R, Giovannelli S, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009;20: 1193-8.